Growing preference for convenient injection of anticoagulants and the introduction of a spectrum of new biotech products is reflecting favorably on the global prefilled auto-injectors market. Over the next couple of years, use of prefilled auto-injectors is expected become widespread across the globe. The product has made self-inject procedures extremely convenient for patients, hence, gaining a significant amount of user trust. In addition, the next generation prefilled auto injectors are more advanced in terms of technology and design. Manufacturers are actively focusing on perfecting prefilled auto-injectors in order to facilitate their use in new therapeutic areas. Prefilled auto-injectors are essentially developed for more reliable and accurate injection. Factors as such are anticipated to further boost the global sales of prefilled auto-injectors. As per the latest report published by Fact.MR, the global prefilled auto injectors market is will surge at 15.3% CAGR during the forecast period (2017-2022).

Customize the Report: https://www.factmr.com/connectus/sample?flag=RC&rep_id=169

Prefilled auto-injectors are primarily intended for self-administration by patients without the obligation of any special training. These injectors come with standard prefilled barrels that contain therapeutic drugs and are easy to use. By design, they are mostly compact and have a pen like shape with a tiny reusable needle attached on the nip. Usually, the site of injection is either thighs or arms, but it may differ on a case-by-case basis or dosage of drug.

In terms of revenue, North America is expected to dominate the global prefilled auto-injectors market over 2022. This is primarily owing to the rising number of patients who require drug administration on regular basis. Owing to the extreme convenience of administrating insulin, prefilled auto injectors are also gaining popularity among patients suffering from diabetes in the region. The prefilled auto injectors market in North America in expected to witness a strong growth over the forecast period. Meanwhile, robust development of the healthcare sector coupled with low cost of prefilled auto-injectors is proving to be instrumental for the growth of the market in Asia-Pacific excluding Japan (APEJ). Between 2017 and 2022, the region’s market is projected to increase at an impressive CAGR of 15.9%.

Based on indication, the anaphylaxis segment currently accounts for more than two-third revenue share of the market. The segment is estimated to reach a market valuation of over US$ 3,187 Mn towards the end of 2022, reflecting a strong CAGR. In addition, the segment is expected to growing at around US$ 320 Mn annually over the course of the assessment period.

Get Report Sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=169

Fact.MR’s report also profiled companies that are expected to remain active in the expansion of global prefilled auto injectors market through 2022, which include Becton, Dickinson and Company, Pfizer Inc., Mylan N.V., Antares Pharma, Inc., Amgen Inc., and Eli Lilly and Company.

About Us

We are an insights-driven global market intelligence company with a unique purpose: enabling organizations make better decisions. We do this by creating an ecosystem where an eclectic cognitive collaboration between human imagination and data science leads to path breaking ideas.

Our vision is to foster a pervasive culture where critical business decisions are taken on the basis of facts rather than assumptions and perceptions.

Our mission is empowerment – empowerment of free-thought; empowerment of fact-based decisions; empowerment of decisive action.

Contact Us

Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Tel: +353-1-4434-232
Tel: +353-1-6111-593